Filana Therapeutics Inc FLNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Stocks to Watch: Nike, Cassava Sciences, KB Home
Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial
Trading Information
- Previous Close Price
- $0.45
- Day Range
- $0.45–0.46
- 52-Week Range
- $0.45–3.45
- Bid/Ask
- $0.45 / $0.46
- Shares Outstanding
- 50.30M
- Market Cap
- $22.70M
- Volume/Avg
- 15,101 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.filanatx.com
Valuation
Metric | FLNA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.38 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | FLNA |
|---|---|
Quick Ratio | 1.12 |
Current Ratio | 1.91 |
Interest Coverage | — |
Quick Ratio
FLNA
Profitability
Metric | FLNA |
|---|---|
Return on Assets (Normalized) | −22.49% |
Return on Equity (Normalized) | −36.46% |
Return on Invested Capital (Normalized) | −40.84% |
Return on Assets
FLNA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|R%WnKb | LOCK|@l!#^ | $138B | |||
| Moderna Inc MRNA | LOCK|#H&@<! | LOCK|D< | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|jdGK?X> | LOCK|^%w>F | $93B | |||
| argenx SE ADR ARGX | LOCK|$%<!#?z | LOCK|YM# | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?y>&$d | LOCK|<s | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|f!qCt%y? | LOCK|n^<@ | $30B | |||
| Incyte Corp INCY | LOCK|NwsBK?> | LOCK|^&z | $24B | |||
| BioNTech SE ADR BNTX | LOCK|f$J>&Ss | LOCK|yYg | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|TCl&&Xp | LOCK|!%hr | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|y@<TFz | LOCK|Vd | $15B |
United States